CN108991358A - A kind of auxiliary reducing blood lipid, it is hypoglycemic, alleviate gout health care food and production method - Google Patents
A kind of auxiliary reducing blood lipid, it is hypoglycemic, alleviate gout health care food and production method Download PDFInfo
- Publication number
- CN108991358A CN108991358A CN201810818634.6A CN201810818634A CN108991358A CN 108991358 A CN108991358 A CN 108991358A CN 201810818634 A CN201810818634 A CN 201810818634A CN 108991358 A CN108991358 A CN 108991358A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- hypoglycemic
- health care
- blood lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 32
- 210000004369 blood Anatomy 0.000 title claims abstract description 32
- 239000008280 blood Substances 0.000 title claims abstract description 32
- 235000013305 food Nutrition 0.000 title claims abstract description 27
- 150000002632 lipids Chemical class 0.000 title claims abstract description 27
- 230000036541 health Effects 0.000 title claims abstract description 26
- 230000002218 hypoglycaemic effect Effects 0.000 title claims abstract description 24
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 8
- 244000130270 Fagopyrum tataricum Species 0.000 claims abstract description 22
- 235000014693 Fagopyrum tataricum Nutrition 0.000 claims abstract description 22
- 229940026314 red yeast rice Drugs 0.000 claims abstract description 20
- 239000001556 apium graveolens l. seed extract Substances 0.000 claims abstract description 19
- 229940116732 celery seed extract Drugs 0.000 claims abstract description 19
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 17
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 17
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 16
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 16
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 16
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 16
- 238000009835 boiling Methods 0.000 claims abstract description 12
- 238000010438 heat treatment Methods 0.000 claims abstract description 7
- 238000001704 evaporation Methods 0.000 claims abstract description 6
- 230000008020 evaporation Effects 0.000 claims abstract description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 11
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 11
- 239000000811 xylitol Substances 0.000 claims description 11
- 235000010447 xylitol Nutrition 0.000 claims description 11
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 11
- 229960002675 xylitol Drugs 0.000 claims description 11
- 229920001353 Dextrin Polymers 0.000 claims description 10
- 239000004375 Dextrin Substances 0.000 claims description 10
- 235000019425 dextrin Nutrition 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 244000269722 Thea sinensis Species 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000013618 particulate matter Substances 0.000 claims description 3
- 241000512259 Ascophyllum nodosum Species 0.000 claims 1
- 241000219051 Fagopyrum Species 0.000 claims 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims 1
- 235000021307 Triticum Nutrition 0.000 claims 1
- 244000098338 Triticum aestivum Species 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 17
- 238000003672 processing method Methods 0.000 abstract description 7
- 230000004927 fusion Effects 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 235000013402 health food Nutrition 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 4
- 239000000470 constituent Substances 0.000 abstract description 3
- 230000002035 prolonged effect Effects 0.000 abstract description 3
- 239000007787 solid Substances 0.000 abstract description 3
- 229960003237 betaine Drugs 0.000 description 15
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
- 230000006870 function Effects 0.000 description 10
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229930182817 methionine Natural products 0.000 description 8
- 229960004452 methionine Drugs 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 201000001431 Hyperuricemia Diseases 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229940116269 uric acid Drugs 0.000 description 5
- 240000007087 Apium graveolens Species 0.000 description 4
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 4
- 235000010591 Appio Nutrition 0.000 description 4
- 229920002567 Chondroitin Polymers 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 230000022558 protein metabolic process Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 229960004203 carnitine Drugs 0.000 description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000001387 apium graveolens Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003716 rejuvenation Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 102100025991 Betaine-homocysteine S-methyltransferase 1 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 101000933413 Homo sapiens Betaine-homocysteine S-methyltransferase 1 Proteins 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- SWHAQEYMVUEVNF-UHFFFAOYSA-N magnesium potassium Chemical compound [Mg].[K] SWHAQEYMVUEVNF-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/60—Edible seaweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to field of health care food, especially a kind of auxiliary reducing blood lipid, hypoglycemic, alleviation gout health care food and its production method, mainly include following components: tartary buckwheat extract, wolfberry fruit extract, Celeryseed extract, Thallus Laminariae (Thallus Eckloniae) extract, chondroitin sulfate, Red Yeast Rice P.E.Pass through the coordinative role of many kinds of substance in this food, can effectively reducing blood lipid, it is hypoglycemic, alleviate gout, the health food absorption of human body effect obtained by the processing method in the application is good, various material compositions are enabled to more fully to mix by prolonged Hybrid Heating by adding each substance to be placed in boiling stoste, substance after mixing in solution is sufficiently deep into various particulate matters, concentration and evaporation is eventually passed through by moisture removal, obtained solid matter is more preferable on the mutual degrees of fusion of constituent content and each component, mutually acts synergistically more obvious.
Description
Technical field
The present invention relates to field of health care food, especially a kind of auxiliary reducing blood lipid, it is hypoglycemic, alleviate gout health care food and
Production method.
Background technique
In recent years, dietary structure is significantly changed due to the generally raising of people's living standard, physical strength is added
The reduction of labour and amount of exercise, therefore expedited the emergence of out a kind of general designation class disease " rich people's disease ": rich people's disease is also known as " modern civilization diseases ":
It after referring to modern life affluence relatively, eats good things, eat smart, overnutrition, activity is reduced, thus some non-biographies generated
The epidemic disease of metachromia.Such as constipation, obesity, bowel cancer, hyperlipidemia, atherosclerosis, coronary heart disease, diabetes, headstroke.With
Living-pattern preservation, the disease incidence of " rich people's disease " is just increasingly high, becomes the main disease for endangering human health.
However, hyperuricemia patients are rising year by year, and tend to rejuvenation, uric acid in blood increases for a long time, can make uric acid
Mineralization is in joint and its surrounding tissue, phenomena such as toe, foot be hot-tempered, knee joint etc. will appear acute severe pain, red and swollen.
If hyperuricemia is not controlled actively, treated, kidney can be also damaged, uric acid nephropathy can be caused.According to investigations, the present uric acid in China
High patient has been up to 1.2 hundred million people, and compared with before 15 years, incidence increases more than 10 times, and rejuvenation trend is obvious.
Gout be look sidelong at ridge dysbolism for a long time, blood uric acid increases one group of different substantiality disease for causing tissue damage.It is clinical special
Point is that hyperuricemia, gouty acute arthritis recurrent exerbation, tophaceous deposition, characteristic chornic arthritis and joint are abnormal
Shape often involves kidney and causes chronic to ask that matter ephritis and kidney calculus urate are formed.The biochemical marker of gout is hyperuricemia, is referred to
The lithate of extracellular fluid is in over-saturation state.Lithate joint and periarticular tissue deposit in crystalline form so as to cause
A series of acute inflammatory reactions, as gout.
It is counted according to " Chinese medicinal application detection ", Patients with Hyperuricemia number in China's is up to 1. 2 hundred million at present, and is urinated by height
The disease rates that acidaemia evolves into gout are about 1/ 10.China's gout number of the infected 2015 oneself up to 75,000,000, and pain
For wind disease incidence every year also with 7.5% speed substantial increase, 1/ 5 gout patients are own to lose viability, goat
People's course of disease is more than 10 years, easily causes the uremia for being difficult to cure, heavy psychological pressure and economy are brought to patient and family
Burden.Hyperuricemia and the diseases such as primary gout and obesity, hyperlipidemia, high blood pressure, diabetes, coronary heart disease manifest
It writes and is positively correlated.Therefore, gout is a kind of serious metabolic disease for endangering human health especially as diabetes.
In conclusion four current high pain wind regimes have drastically influenced people and normally lived, people is reduced
Quality of life, mainly pass through drug when being treated for above-mentioned illness now and treated, but simple want
Go treatment that cannot play complete rehabilitative action for the moment, and being used for a long time will go treatment that there can be many side effects, therefore
It is mainly treated in such a way that health care dietotherapy and drug therapy combine at present, but the health care function of present health food
Can be relatively single, when the above-mentioned complicated various diseases of face combine, a kind of simple health care product can not effectively comprehensively
To play the role of ancillary drug treatment.
Summary of the invention
The present invention is at least to solve technical solution used by one of above-mentioned technical problem to be: a kind of auxiliary reducing blood lipid is dropped
Blood glucose, alleviate gout health care food, mainly include following components: tartary buckwheat extract, wolfberry fruit extract, Celeryseed extract,
Thallus Laminariae (Thallus Eckloniae) extract, chondroitin sulfate, Red Yeast Rice P.E.
10-35 parts of tartary buckwheat extract, 10-40 parts of wolfberry fruit extract, 10-35 parts of Celeryseed extract, Thallus Laminariae (Thallus Eckloniae) extract
10-40 parts, 10-35 parts of chondroitin sulfate, 20-45 parts of Red Yeast Rice P.E.
It further include the component of parts by weight: 10-25 parts of xylitol.
It further include the component of following parts by weight: 1-5 parts of magnesium stearate, 10-25 parts of dextrin.
It mainly comprises the following components in parts by weight: 25 parts of tartary buckwheat extract, 30 parts of wolfberry fruit extract, Celeryseed extract
25 parts, 25 parts of Thallus Laminariae (Thallus Eckloniae) extract, 20 parts of chondroitin sulfate, 30 parts of Red Yeast Rice P.E, 15 parts of xylitol, 3 parts of magnesium stearate, dextrin
20 parts.
It is a kind of to assist reducing blood lipid, production method that is hypoglycemic, alleviating gout health care food, the specific steps of which are as follows:
S1: each component is crushed and is classified individually placed by ratio by weight respectively；
S2: smashed tartary buckwheat extract, wolfberry fruit extract, Celeryseed extract, Thallus Laminariae (Thallus Eckloniae) extract are put into nothing in proportion
In bacterium reaction vessel, the boiling stoste mixed up in advance, heat temperature raising is added；
S3: mixed liquor is stirred continuously in heating process；
S4: after solution boils for the first time, smashed chondroitin sulfate, Red Yeast Rice P.E are proportionally added into；
S5: being added cold water, is boiled by slow fire simultaneously isothermal holding 1 hour；
S6: it is concentrated by evaporation, removes water to obtain particulate matter；
S7: it is dried, obtains product.
The boiling stoste is aqueous tea leaf solution.
Beneficial effect possessed by the present invention is, by the coordinative role of many kinds of substance in this food, can effectively to drop
Blood lipid, hypoglycemic, alleviation gout, the health food absorption of human body effect obtained by the processing method in the application is good, passes through
Add each substance to be placed in boiling stoste enables to various material compositions more fully mixed by prolonged Hybrid Heating
It closes, the substance after mixing in solution is sufficiently deep into various particulate matters, eventually passes through concentration and evaporation for moisture removal, obtain
Solid matter it is more preferable on the mutual degrees of fusion of constituent content and each component, mutually act synergistically more obvious.
Specific embodiment
In order to clarify the technical characteristics of the invention, being explained in detail below by specific embodiment the present invention
It states.
Embodiment 1:
A kind of auxiliary reducing blood lipid, it is hypoglycemic, alleviate gout health care food, mainly include following components: tartary buckwheat extract, fructus lycii
Extract, Celeryseed extract, Thallus Laminariae (Thallus Eckloniae) extract, chondroitin sulfate, Red Yeast Rice P.E.
Preferably, it mainly comprises the following components in parts by weight: 25 parts of tartary buckwheat extract, 30 parts of wolfberry fruit extract, celery
25 parts of seed extract, 25 parts of Thallus Laminariae (Thallus Eckloniae) extract, 20 parts of chondroitin sulfate, 30 parts of Red Yeast Rice P.E, 15 parts of xylitol, magnesium stearate
3 parts, 20 parts of dextrin；Tartary buckwheat has hypoglycemic, reducing blood lipid, enhances human immunity, treats stomach disease, removing dampness and detoxicating, controls ephritis, erosion
The effect of disliking meat in vivo, has auxiliary therapeutic action to diabetes, hypertension, hyperlipidemia, coronary heart disease, apoplexy, patients with gastric disease, together
When tartary buckwheat extract can reduce the blood lipid and liver index of experimental atherosclerosis rats, improve the oxidation resistance of blood, subtract
Oxidative damage caused by light high fat diet, may be implemented hypoglycemic, lipid-lowering effect by tartary buckwheat；And without insulin and antidiabetic drug
Side effect.Co-Q10, Co-Q10 also known as Ubiquinone-50 are separated after red koji fermentation, are the activation of cell metabolism and cellular respiration
Agent can improve mitochondrial respiratory function, promote oxidative phosphorylation reaction.Itself is the Native Oxide that cell itself generates again
Agent can inhibit the peroxidating of mitochondria, there is the function of protection biofilm structure integrality.There is non-specific enhancing to make to immune
With can improve the phagocytic rate of phagocyte, increase the generation of antibody, improve T cell function.
With reinforcing spleen to promote digestion, the effect of activating microcirculation and removing stasis medicinal；For reducing blood lipid, total cholesterol is reduced, reductase inhibitor, directly
Inhibit HNG-coA reductase, blocks cholesterol biosynthesis；Heterozygosis can be effectively reduced in type familial and non-in Lovastatin (Mevacor)
The serum cholesterol content of familial hypercholesterolemia card patient.
Wolfberry fruit extract main component is polysaccharides, interior to contain a large amount of fructus lycii glycine betaine.
The most important physiological function of glycine betaine is that methyl and adjusting body osmotic pressure are provided for body.As methyl donor,
Glycine betaine is recycled in the liver and kidney of animal by methionine, and the important metabolic pathway of body is participated in；As osmotic pressure tune
Object is saved, glycine betaine is mainly able to maintain that cell normal volume, the structure and function of protection cell membrane, albumen and enzyme.
For methyl function: methyl (- CH3) is animal body metabolism, especially base necessary to protein and fat metabolism
Group, body itself are unable to synthesizing methyl, need to be provided by foreign donor.Glycine betaine, choline and methionine, which are that animal body is main, to be had
Imitate methyl donor.Glycine betaine contains 3 polarity methyl, is direct, effective methyl donor substance.Glycine betaine can not only mention
For active methyl, and methionine cycle-index can be increased by the catalytic action of BHMT, enhance body methyl metabolism, add
The processes such as the processing and modification of fast DNA.
Regulatory protein metabolism: glycine betaine can make crude protein, ribonucleic acid, RNA and DNA in animal's liver and muscle
Ratio significantly improve, serum uric acid is decreased obviously, participate in adjust body protein metabolism.Glycine betaine participates in synthesis creatine, phosphorus
Rouge, adrenaline, ribonucleic acid, DNA etc. are a variety of to have important physiological function substance, promotes body protein
Synthesis, reduces the degradation of protein, increases the deposition of protein in tissue.Glycine betaine can partially substitute methionine for methyl
Function, reduce methionine for methyl consumption, improve its utilization efficiency.Methionine is not only the original of body protein synthesis
Material, and can also participate in adjusting body protein metabolism, it plays an important role in protein metabolism.
Adjust fat metabolism: body fat deposition is by Exogenous fatty intake, endogenous Fatty synthesis and fatty acid beta oxidation
The dynamic process of co-determination.Therefore, when external source fat intake is horizontal identical, Body fat retention reduction depends primarily on fat
It decomposes to increase and be reduced with endogenous Fatty synthesis.Glycine betaine can synthesize for carnitine and provide methyl, accelerate carnitine synthesis, improve broiler chicken
The content of carnitine in liver accelerates transhipment and decomposition of the fatty acid to mitochondria, to reduce body fat deposition.Glycine betaine
Hormonal readiness and the growth factor of controllable body and the decomposition and anabolism for adjusting body fat.
Osmotic pressure is adjusted, for maintaining the albumen of cell and the structure function of enzyme under stressed condition, cell normal volume, thin
Born of the same parents' is that outlet capacity and cell eubolism play an important role.
Anti-oxidation function: glycine betaine mainly passes through following three approach and plays its anti-oxidation function: methionine circulation is participated in,
Raising methionine and SAM content, the generation of the important metabolites such as promotion cystine, glutathione, and these metabolites
It plays a significant role in body antioxidant system, especially GSH, can directly remove intracorporal active oxygen and hydrogen peroxide, it is right
Body anti-oxidative defense and the stabilization of cell membrane are all of great significance；Body osmotic pressure is adjusted, to the structure and function of cell, enzyme
It can shield, enhance the stability of antioxidase；To phospholipid bilayer rise stabilization, reduce free radical generate and it is right
The damage of cell；Glycine betaine be lipophilic substance can quickly through phospholipid bilayer and can be generated with it particular biological hand over
Interaction reduces Cell membrane lipids peroxidating.
Bacteria resistance function: the activity that glycine betaine reduces moisture in bacterial body is related, to interfere the water metabolism of bacterium, inhibits
The metabolism of bacterium.
Containing expect by oleyl alcohol, phosphorus methoxyl group, umbrella spends interior vinegar, apiolin, linolenic acid, volatility grease, Huang Zitong, coral, mineral
Matter is such as: calcium town, is received, is polished.The contained decompression of celery seed, lipid-loweringing ingredient are 50 times of celery, take play blood pressure lowering in short term, drop blood
The effect of rouge takes for a long time and is far superior to other Pharmaceuticals, without any side effects.The calcium phosphorus content of celery seed is higher, institute
To there is certain calm and protection blood vessel, and bone can be enhanced, prevent infantile osteomalacia.It is main in anti-trioxypurine diuretic compositions
If celery oil and yellow reward, rich in minerals such as unsaturated fatty acid, amino acid and potassium magnesium in celery oil.
By be added after Thallus Laminariae (Thallus Eckloniae) extract can make to have in this product reducing blood lipid, it is hypoglycemic, adjust immune, anticoagulation,
Antitumor, lead discharging removing toxic substances and a variety of biological functions such as anti-oxidant.
It can be made to be used cooperatively with Glucosamine by the way that chondroitin sulfate is added, there is analgesic, promote regenerating bone or cartilage
The effect of, joint prob can be improved from basic.
Xylitol is the intermediate of human body carbohydate metabolism, in the case of lacking insulin influence glycometabolism in vivo, without pancreas
Island element promotes, and xylitol can also penetrate cell membrane, be absorbed by tissue utilization, promotes liver glycogen synthesis, for cell with nutrition and energy
Amount, and blood glucose value will not be caused to increase, more than three symptoms after diabetes patient takes (more foods, more drinks, diuresis) is eliminated, is most suitable
The sugar substitutes of the trophism of patients with diabetes mellitus.
Magnesium stearate wherein primarily as the effect of suspending agent, thickener, can effectively promote in solution heating
Make each substance be combined with each other in the process, improves the viscosity of whole solution, guarantee being sufficiently mixed and uniting between substance.
Dextrin can increase the consistency of product, and the structure of stable prod improves taste and flavor.
It is a kind of to assist reducing blood lipid, production method that is hypoglycemic, alleviating gout health care food, the specific steps of which are as follows:
S1: each component is crushed and classifies individually placed by ratio by weight respectively, is mutually dissolved after crushing convenient for subsequent；
S2: smashed tartary buckwheat extract, wolfberry fruit extract, Celeryseed extract, Thallus Laminariae (Thallus Eckloniae) extract are put into nothing in proportion
In bacterium reaction vessel, the boiling stoste mixed up in advance is added, heat temperature raising will carry out the molten of first batch first after a collection of component
Solution, what can be read fastly will carry out mutually adequately permeating and merging between each substance, so as to melt the formation of each component
Close uniform solution or semi-fluid shape liquid；
S3: being stirred continuously mixed liquor in heating process, effectively improves the abundant degree of fusion, when using convenient for subsequent consumption person
It improves absorption efficiency, improve effect；
S4: after solution boils for the first time, it is proportionally added into smashed chondroitin sulfate, Red Yeast Rice P.E, to completion for the first time
After add second batch substance and adequately merged, the uniformity of material mixing can be improved；
S5: being added cold water, is boiled by slow fire simultaneously isothermal holding 1 hour, can guarantee that substance is issued in high temperature action after being boiled by slow fire
Raw adequately dissolution and synergistic effect, so that the mass action of mixture be made to be higher than individually each individually simple group of substance
Effect when conjunction improves the whole use and therapeutic effect of product；
S6: it is concentrated by evaporation, removes water to obtain particulate matter；
S7: being dried, obtain product, it is dry after product be substance after being handled by above-mentioned steps, between each substance
Degrees of fusion it is more abundant, can more accurately guarantee the small packing band of each identical weight in subsequent large batch of packing
The component of interior substance keep identical substantially, reduce the differentiation of product, improve the unitized and standardization of product.
The boiling stoste is aqueous tea leaf solution, and tealeaves belongs to strong basicity food, can effectively alleviate gout, by boiling
The boiling resulting aqueous tea leaf solution of tealeaves through practicing substance therein during boiling can adequately with it is each in this product
A substance interpenetrates, so that the substance entirely obtained can contain the alkaline matter in more tealeaves, and this method
Resulting alkaline matter is different with the resulting effect of simple placement tealeaves and synergy, passes through the resulting food of this law
Effect is more obvious in terms of alleviating gout.
Embodiment 2:
A kind of auxiliary reducing blood lipid, it is hypoglycemic, alleviate gout health care food, mainly include following components: tartary buckwheat extract, fructus lycii
Extract, Celeryseed extract, Thallus Laminariae (Thallus Eckloniae) extract, chondroitin sulfate, Red Yeast Rice P.E.
10 parts of tartary buckwheat extract, 10 parts of wolfberry fruit extract, 10 parts of Celeryseed extract, 10 parts of Thallus Laminariae (Thallus Eckloniae) extract, sulfuric acid
10 parts of chondroitin, 20 parts of Red Yeast Rice P.E, 10 parts of xylitol, 1 part of magnesium stearate, 10 parts of dextrin.
Processing method is the same as embodiment 1.
Embodiment 3:
A kind of auxiliary reducing blood lipid, it is hypoglycemic, alleviate gout health care food, mainly include following components: tartary buckwheat extract, fructus lycii
Extract, Celeryseed extract, Thallus Laminariae (Thallus Eckloniae) extract, chondroitin sulfate, Red Yeast Rice P.E.
15 parts of tartary buckwheat extract, 20 parts of wolfberry fruit extract, 20 parts of Celeryseed extract, 25 parts of Thallus Laminariae (Thallus Eckloniae) extract, sulfuric acid
15 parts of chondroitin, 20 parts of Red Yeast Rice P.E, 25 parts of xylitol, 2 parts of magnesium stearate, 18 parts of dextrin.
Processing method is the same as embodiment 1.
Embodiment 4:
A kind of auxiliary reducing blood lipid, it is hypoglycemic, alleviate gout health care food, mainly include following components: tartary buckwheat extract, fructus lycii
Extract, Celeryseed extract, Thallus Laminariae (Thallus Eckloniae) extract, chondroitin sulfate, Red Yeast Rice P.E.
30 parts of tartary buckwheat extract, 35 parts of wolfberry fruit extract, 30 parts of Celeryseed extract, 30 parts of Thallus Laminariae (Thallus Eckloniae) extract, sulfuric acid
20 parts of chondroitin, 25 parts of Red Yeast Rice P.E, 20 parts of xylitol, 4 parts of magnesium stearate, 20 parts of dextrin.
Processing method is the same as embodiment 1.
Embodiment 5:
A kind of auxiliary reducing blood lipid, it is hypoglycemic, alleviate gout health care food, mainly include following components: tartary buckwheat extract, fructus lycii
Extract, Celeryseed extract, Thallus Laminariae (Thallus Eckloniae) extract, chondroitin sulfate, Red Yeast Rice P.E.
35 parts of tartary buckwheat extract, 40 parts of wolfberry fruit extract, 35 parts of Celeryseed extract, 40 parts of Thallus Laminariae (Thallus Eckloniae) extract, sulfuric acid
35 parts of chondroitin, 45 parts of Red Yeast Rice P.E, 25 parts of xylitol, 5 parts of magnesium stearate, 25 parts of dextrin.
Processing method is the same as embodiment 1.
By the coordinative role of many kinds of substance in this food, can effectively reducing blood lipid, it is hypoglycemic, alleviate gout, pass through
The health food absorption of human body effect that processing method in the application obtains is good, is led to by adding each substance to be placed in boiling stoste
Crossing prolonged Hybrid Heating enables to various material compositions more fully to mix, and the substance after mixing in solution is sufficiently deep
Enter into various particulate matters, eventually passes through concentration and evaporation for moisture removal, obtained solid matter is in constituent content and each group
It is more preferable on the mutual degrees of fusion divided, it mutually acts synergistically more obvious.
Above-mentioned specific embodiment cannot function as limiting the scope of the invention, for the technology people of the art
For member, any alternate modification or transformation made to embodiment of the present invention are fallen within the scope of protection of the present invention.
Place is not described in detail by the present invention, is the well-known technique of those skilled in the art of the present technique.
Claims (7)
1. a kind of auxiliary reducing blood lipid, hypoglycemic, alleviation gout health care food, it is characterised in that: mainly include following components: bitter buckwheat
Wheat extract, wolfberry fruit extract, Celeryseed extract, Thallus Laminariae (Thallus Eckloniae) extract, chondroitin sulfate, Red Yeast Rice P.E.
2. a kind of auxiliary reducing blood lipid, hypoglycemic, alleviation gout health care food, it is characterised in that: mainly including following parts by weight
Component: 10-35 parts of tartary buckwheat extract, 10-40 parts of wolfberry fruit extract, 10-35 parts of Celeryseed extract, Thallus Laminariae (Thallus Eckloniae) extract 10-
40 parts, 10-35 parts of chondroitin sulfate, 20-45 parts of Red Yeast Rice P.E.
3. a kind of auxiliary reducing blood lipid according to claim 2, hypoglycemic, alleviation gout health care food, it is characterised in that: also
Component including parts by weight: 10-25 parts of xylitol.
4. a kind of auxiliary reducing blood lipid according to claim 3, hypoglycemic, alleviation gout health care food, it is characterised in that: also
It comprises the following components in parts by weight: 1-5 parts of magnesium stearate, 10-25 parts of dextrin.
5. a kind of auxiliary reducing blood lipid according to claim 4, hypoglycemic, alleviation gout health care food, it is characterised in that: main
It comprises the following components in parts by weight: 25 parts of tartary buckwheat extract, 30 parts of wolfberry fruit extract, 25 parts of Celeryseed extract, kelp
25 parts of extract, 20 parts of chondroitin sulfate, 30 parts of Red Yeast Rice P.E, 15 parts of xylitol, 3 parts of magnesium stearate, 20 parts of dextrin.
6. a kind of auxiliary reducing blood lipid according to any one of claim 4 or 5, it is hypoglycemic, alleviate gout health care food
Production method, the specific steps of which are as follows:
S1: each component is crushed and is classified individually placed by ratio by weight respectively；
S2: smashed tartary buckwheat extract, wolfberry fruit extract, Celeryseed extract, Thallus Laminariae (Thallus Eckloniae) extract are put into nothing in proportion
In bacterium reaction vessel, the boiling stoste mixed up in advance, heat temperature raising is added；
S3: mixed liquor is stirred continuously in heating process；
S4: after solution boils for the first time, smashed chondroitin sulfate, Red Yeast Rice P.E are proportionally added into；
S5: being added cold water, is boiled by slow fire simultaneously isothermal holding 1 hour；
S6: it is concentrated by evaporation, removes water to obtain particulate matter；
S7: it is dried, obtains product.
7. a kind of auxiliary reducing blood lipid according to claim 6, production method that is hypoglycemic, alleviating gout health care food:
The boiling stoste is aqueous tea leaf solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810818634.6A CN108991358A (en) | 2018-07-24 | 2018-07-24 | A kind of auxiliary reducing blood lipid, it is hypoglycemic, alleviate gout health care food and production method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810818634.6A CN108991358A (en) | 2018-07-24 | 2018-07-24 | A kind of auxiliary reducing blood lipid, it is hypoglycemic, alleviate gout health care food and production method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108991358A true CN108991358A (en) | 2018-12-14 |
Family
ID=64597740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810818634.6A Pending CN108991358A (en) | 2018-07-24 | 2018-07-24 | A kind of auxiliary reducing blood lipid, it is hypoglycemic, alleviate gout health care food and production method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108991358A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116139231A (en) * | 2022-12-26 | 2023-05-23 | 珠海脉氪生物科技有限公司 | Compositions for specific dissolution of urate crystals in joints |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150140178A1 (en) * | 2014-08-07 | 2015-05-21 | Mingfu LU | Complete Nutritional Powder and Preparation Method Thereof |
| CN105310075A (en) * | 2015-09-23 | 2016-02-10 | 威海南波湾生物技术有限公司 | Preparation method of natto red yeast rice health care food for assisting in lowering blood lipid |
| CN106666312A (en) * | 2017-01-11 | 2017-05-17 | 大连雅威特生物技术股份有限公司 | Health-care food for assisting blood glucose decreasing and preparation method of granule and capsule thereof |
-
2018
- 2018-07-24 CN CN201810818634.6A patent/CN108991358A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150140178A1 (en) * | 2014-08-07 | 2015-05-21 | Mingfu LU | Complete Nutritional Powder and Preparation Method Thereof |
| CN105310075A (en) * | 2015-09-23 | 2016-02-10 | 威海南波湾生物技术有限公司 | Preparation method of natto red yeast rice health care food for assisting in lowering blood lipid |
| CN106666312A (en) * | 2017-01-11 | 2017-05-17 | 大连雅威特生物技术股份有限公司 | Health-care food for assisting blood glucose decreasing and preparation method of granule and capsule thereof |
Non-Patent Citations (3)
| Title |
|---|
| 卢卫红等: "《食品功能原理及评价 上》", 31 October 2014, 哈尔滨工业大学 * |
| 王淑君等: "《保健食品研发与制作》", 31 August 2009, 人民军医出版社 * |
| 贾天柱: "《中药炮制学》", 31 August 2008, 海洋学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116139231A (en) * | 2022-12-26 | 2023-05-23 | 珠海脉氪生物科技有限公司 | Compositions for specific dissolution of urate crystals in joints |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eliseeva et al. | Vitamin C (ascorbic acid)–description, benefits and where it is found | |
| CN101473953B (en) | Fabricated food for cleaning blood and expelling toxin as well as method for processing the same and application | |
| CN102077934B (en) | Special dietary marine food for patients with high blood pressure | |
| CN102077940B (en) | Special dietary marine food for patients with coronary heart disease | |
| CN102077936A (en) | Special sea dietary food for diabetics | |
| CN102077937B (en) | Special dietary seafood special for young and middle-aged women | |
| CN102077938B (en) | Special marine dietary food for patients with liver deficiency | |
| CA2514687A1 (en) | Advenced vitamin c-based composition with enhanced biotransformation and utilization of protein and l-carnitine for nutritional supplementation or the like | |
| CN102077939A (en) | Marine special dietary food special for fat people | |
| CN102077945A (en) | Special dietary seafood for postabortal and postpartum women | |
| CN102077944B (en) | Marine special dietary food special for prostate patient | |
| JP4132635B2 (en) | Uninactivated enzyme-enhanced composition | |
| CN110214942A (en) | A kind of hyperthyroidism tailored version Nutrition formula and preparation method thereof | |
| RU2283124C1 (en) | Biologically active preparation based on marine vegetable raw | |
| CN105410930A (en) | Health-care product with weight-losing and body-slimming and nutrition-balancing functions and preparation method thereof | |
| CN102077943B (en) | Seafood for special dietary uses for hypomnesia patients | |
| CN108991358A (en) | A kind of auxiliary reducing blood lipid, it is hypoglycemic, alleviate gout health care food and production method | |
| CN111467468A (en) | Concentrated nutrient solution containing ginseng, cordyceps militaris, ginger and wolfberry fruit and preparation method thereof | |
| CN109965072A (en) | A kind of pressed candy and the preparation method and application thereof conserving liver | |
| CN109805235B (en) | Wheat-flavor composite polypeptide solid beverage for assisting in reducing hypertension, hyperglycemia and hyperlipidemia, and preparation method and application thereof | |
| CN102511882A (en) | Red jujube thick syrup beneficial for improving growth and development | |
| CN105995980A (en) | Composition with weight management function and preparation method thereof | |
| WO2008146050A1 (en) | Medicinal-preventive nutrient combination and foodstuffs on the basis thereof | |
| CN1067270C (en) | Nutritious health care medicine | |
| RU2809638C1 (en) | Product specialized with arginine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181214 |